## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.89 indicates fundamental undervaluation. Quality metrics strong (ROE 31%). Caution: declining volume (56% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($60.81)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 1, Bearish: 8)

**1. Bragar Eagel & Squire, P.C. Urges DexCom and Wildermuth Investors to Contact the Firm Regarding Their Rights Before Upcoming Deadlines**
- Source: GlobeNewswire | 20251204T231311 | Bearish | Relevance: 100%
- Bragar Eagel & Squire, P.C., a shareholder rights law firm, reminds investors of DexCom, Inc. and Wildermuth Fund about upcoming deadlines to serve as lead plaintiff in class action lawsuits. The DexCom lawsuit alleges false and misleading statements about the G6 and G7 devices, while the Wildermuth Fund lawsuit claims miscalculation of investment fair value and intentional inflation of net asset value. Investors in both companies are encouraged to contact the firm regarding their rights.

**2. DexCom, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before December 26, 2025 to Discuss Your Rights – DXCM**
- Source: KLAS 8 News Now | 20251204T211220 | Bearish | Relevance: 100%
- DexCom, Inc. is facing a class action securities lawsuit alleging that the company made unauthorized design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and potentially harmful. Investors who suffered losses between January 8, 2024, and September 17, 2025, are encouraged to contact Levi & Korsinsky, LLP by December 26, 2025, to discuss their rights and potentially serve as a lead plaintiff. The lawsuit claims that DexCom overstated the enhancements and reliability of the G7 device, while downplaying significant issues and health risks, leading to an increased risk of regulatory scrutiny and financial harm.

**3. Key facts: Class Action Filed Against DexCom; Company Launches Academy**
- Source: TradingView | 20251204T200905 | Somewhat-Bearish | Relevance: 100%
- A class action lawsuit has been filed against DexCom, Inc. (DXCM) alleging securities fraud between January 8, 2024, and September 17, 2025. Concurrently, DexCom has launched Dexcom Academy, an educational initiative aimed at providing healthcare professionals with enhanced training in diabetes management.

**4. DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm**
- Source: GlobeNewswire | 20251204T150947 | Bearish | Relevance: 100%
- The Schall Law Firm is reminding investors of a class action lawsuit against DexCom, Inc. (NASDAQ: DXCM) for alleged securities fraud. The lawsuit claims that DexCom made false and misleading statements by changing its G6 and G7 systems without FDA authorization, leading to less reliable products and health risks for users. Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, are encouraged to contact the firm before December 26, 2025, to discuss their rights.

**5. Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy**
- Source: Business Wire | 20251204T130941 | Bullish | Relevance: 100%
- DexCom, Inc. (NASDAQ: DXCM) has launched Dexcom Academy, a new personalized learning platform designed with and for healthcare professionals (HCPs) to strengthen their confidence in continuous glucose monitoring (CGM) use and support high-quality diabetes care. This platform, available as both desktop learning and a mobile app, offers flexible, bite-sized modules based on HCP feedback, addressing the need for tailored education that fits into busy schedules. Dexcom Academy is currently available in five countries across EMEA, with further expansion planned.

### Analyst Activity

**Target Signal:** BEARISH (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |
| 2025-11-10 | Morgan Stanley | $63 | $89 | -29% |
| 2025-11-07 | Argus Research | $90 | $100 | -10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |
| 2025-11-10 | Morgan Stanley | main | Equal-Weight |
| 2025-11-07 | Argus Research | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)
- JPMORGAN CHASE & CO: 3.2% (+101.9%)

### Key Risks

1. Long-term trend broken: trading 13.2% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.89 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.5B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.89 |
| Forward P/E | 26.3 |
| Current P/E | 31.6 |
| YoY Growth | 20.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 5.8% (minimal 5-day change). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 87th percentile. MRS_5 at 1.0% confirms short-term momentum alignment. AM_20 at 8.0% shows strong absolute momentum above own 20MA. Outperforming sector by 7.2pp, stock-specific strength. Below SMA200 (0.87x), long-term trend not supportive. MACD histogram positive (0.97), confirming momentum. RSI neutral at 59. Volume at 56% of 20MA suggests lack of conviction. OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.76% (CS: 87) | Strong |
| RSI_14 | 58.6 | Neutral |
| MACD Histogram | 0.97 | Bullish |
| vs SMA20 | 1.080x | Above |
| vs SMA50 | 1.018x | Above |
| vs SMA200 | 0.868x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $65.25
- **Stop Loss:** $60.81 (6.8% risk)
- **Target:** $74.13 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 112
- **Position Value:** $7,308.00
- **Portfolio %:** 7.31%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*